YMDD mutations and genotypes of hepatitis B virus in northern China

Japanese Journal of Infectious Diseases

Volumn 59, Issue 1, 2006, Pages 42-45

  Li, Di ^a   Gu, Hong Xi ^a   Zhang, Shu Yun ^a   Zhong, Zhao Hua ^a   Zhuang, Min ^a,b   Hattori, Toshio ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; METHIONINE; TYROSINE; VALINE; VIRUS DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ARTICLE; CHINA; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS GENE; VIRUS MUTATION;

ANTIVIRAL AGENTS; CHINA; DNA MUTATIONAL ANALYSIS; GENES, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33644540209     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Suzuki, Y., Kumada, H., Ikeda, K., Chayama, K., Arase, Y., Saitoh, S., Tsubota, A., Kobayashi, M., Koike, M., Ogawa, N. and Tanikawa, K. (1999): Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol., 30, 743-748.
2. Kidd-Ljunggren, K., Miyakawa, Y. and Kidd, A. H. (2002): Genetic variability in hepatitis B viruses. J. Gen. Virol., 83, 1267-1280.
3. Arauz-Ruiz, P., Norder, H., Robertson, B. H. and Magnius, L. O. (2002): Genotype H: A new Amerindian genotype of hepatitis B virus revealed in Central America. J. Gen. Virol., 83, 2059-2073.
4. Moriyama, M., Taira, M., Matsumura, H., Aoki, H., Mikuni, M., Kaneko, M., Shioda, A., Iwaguchi, K., Arai, S., Ichijima, S., Iwasaki, H., Tanaka, N., Abe, K. and Arakawa, Y. (2003): Genotype analysis, using PCR with type-specific primers, of hepatitis B virus isolates from patients coinfected with hepatitis delta virus genotype II from Miyako Island, Japan. Intervirology, 46, 114-120.
5. Miyakawa, Y. and Mizokami, M. (2003): Classifying hepatitis B virus genotypes. Intervirology, 46, 329-338.
6. Chu, C. J., Keeffe, E. B., Han, S. H., Perrillo, R. P., Min, A. D., Soldevila-Pico, C., Carey, W., Brown, R. S., Jr., Luketic, V. A., Terrault, N. and Lok, A. S. (2003): Hepatitis B virus genotypes in the United States: Results of a nationwide study. Gastroenterology, 125, 444-451.
7. Yuen, M. F., Sablon, E., Yuan, H. J., Wong, D. K., Hui, C. K., Wong, B. C., Chan, A. O. and Lai, C. L. (2003): Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology, 37, 562-567.
8. Naito, H., Hayashi, S. and Abe, K. (2001): Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using typespecific primers. J. Clin. Microbiol., 39, 362-364.
9. Moskoviz, D. N., Osiowy, C., Giles, E., Tomlinson, G. and Heathcote, E. J. (2005): Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J. Viral Hepat., 12, 398-404.
10. Atkins, M., Hunt, C. M., Brown, N., Gray, F., Sanathanan, L., Woessner, M., Lai, C. I., Dusheiko, G., Dienstag, J., Wright, T., Bamard, J., Bourne, E. and Condreay, L. (1998): Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients (Abstract). Hepatology, 8, 319.
11. Leung, N. W., Lai, C. L., Chang, T. T., Guan, R., Lee, C. M., Ng, K. Y., Lim, S. G., Wu, P. C., Dent, J. C., Edmundson, S., Condreay, L. D. and Chien, R. N; On behalf of the Asia (2001): Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 33, 1527-1532.
12. Niesters, H. G., Honkoop, P., Haagsma, E. B., de Man, R. A., Schalm, S. W. and Osterhaus, A. D. (1998): Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis., 177, 1382-1385.
13. Akuta, N., Suzuki, F., Kobayashi, M., Matsuda, M., Sato, J., Takagi, K., Tsubota, A., Suzuki, Y., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Arase, Y., Ikeda, K. and Kumada, H. (2003): Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J. Med. Virol., 71, 504-510.
14. Kao, J. H., Liu, C. J. and Chen, D. S. (2002): Hepatitis B viral genotypes and lamivudine resistance. J. Hepatol., 36, 303-304.
15. Tomokuni, N., Tatsuji, M., Tomofumi, N., Hiroki, N., Hiroshi, S., Fukunori, K., Etsuro, O. and Masashi, M. (2003): Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa islands: A prospective study. J. Med. Virol., 70, 350-354.
16. Gu, H. X., Xu, Z. L., Liu, J. Y., Zhong, Z. H., Wang, H. Q., Zhang, S. Y., Li, D., Zhang, H. H. and Abe, K. (2004): Epidemiology of HBV genotypes by nested PCR with multi-paired primers. World Chin. J. Digestol., 12, 1073-1076 (in Chinese).
17. Dong, M. and Zhong, Y. X. (2005): Distridution of hepatitis B virus genotypes and its clinical significance. Chin. J. Hepatol., 13, 56-57 (in Chinese).
18. Suzuki, F., Tsubota, A., Arase, Y., Suzuki, Y., Akuta, N., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Ikeda, K., Kobayashi, M., Matsuda, M., Satoh, J., Takagi, K. and Kumada, H. (2003): Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology, 46, 182-489.
19. Akuta, N., Suzuki, F., Kobayashi, M., Tsubota, A., Suzuki, Y., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Arase, Y., Ikeda, K. and Kumada, H. (2003): The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol., 38, 315-321.
20. Yuen, M. F., Wong, D. K., Sablon, E., Yuan, H. J., Sum, S. M., Hui, C. K., Chan, A. O., Wang, B. C. and Lai, C. L. (2003): Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir. Ther., 8, 531-534.
21. Wang, G. Y., Zhu, W. J. and Yang, X. L. (2005): YMDD mutation of hepatitis B virus and genotyping in Guiyang region. Chin. J. Hepatol., 13, 193-195 (in Chinese).
22. Zhou, J. L. and Wu, S. P. (2004): Effects of comparison of lamivudine therapy B virus genotype B and C. Chin. J. Hepatol., 12, 489-490 (in Chinese).
23. Zollner, B., Petersen, J., Puchhammer-Stockl, E., Kletzmayr, J., Sterneck, M., Fischer, L., Schroter, M., Laufs, R. and Feucht, H. H. (2004): Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology, 39, 42-50.
24. Zhang, X., Liu, C., Gong, Q., Zhang, S., Zhang, D., Lu, Z. and Wang, Y. (2003): Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J. Gastroenterol. Hepatol., 18, 1353-1357.